Novo Nordisk (NYSE: NVO) is a global healthcare company engaged in diabetes care, obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other … [Read more...] about Is Novo Nordisk Ready For Increased Biosimilar Competition?
On August 27th, 2018 MS Money Moves initiated coverage on Adamis Pharmaceuticals (ADMP). At the time it was trading at $2.85 per share. Our analysis of the company indicated that it was oversold and … [Read more...] about ADMP Poised For NDA Approval